Skip to main content
Clinical Trials/NCT03905356
NCT03905356
Completed
N/A

Exercise Therapy in Radiation Therapy (EXERT)

Milton S. Hershey Medical Center1 site in 1 country16 target enrollmentFebruary 12, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Metastatic Cancer
Sponsor
Milton S. Hershey Medical Center
Enrollment
16
Locations
1
Primary Endpoint
Incidence of Treatment- Emergent Adverse Events
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to evaluate exercise therapy as a method for potentially improving radiation therapy treatment toxicities for metastatic cancer patients receiving radiation therapy.

Detailed Description

Study Objectives and Endpoints: Aim 1. To determine the acceptability, feasibility, and safety of an exercise intervention among cancer patients receiving radiation therapy. The investigators anticipate that \>25% of approached patients will consent to the protocol; \>33% of eligible radiation therapy patients who consent will perform the exercise prescribed (based on the response rate from EnACT); and \<25% of participants will experience a musculoskeletal impairment (without treatment alterations) and \<5% will experience a musculoskeletal injury with symptoms lasting ≥ week or requiring medical attention. The investigators' approach will be to include patients receiving definitive RT; excluding patients at high risk for side effects from combination therapy, including fracture or cardiovascular events. Aim 2. To discern the clinical outcomes of patients receiving RT+ET. The hypothesis is that adding ET to RT will improve patient reported outcomes and physical functioning. The investigators' approach will be to use standardized questionnaires and assessment tools: patient reported outcomes will be assessed using Common Terminology Criteria for Adverse Events - Patient Reported Outcomes (CTCAE-PROs), loaded onto tablets that patients use in the clinic. Questions will assess global PROs relevant to the ability to tolerate RT, including fatigue, pain, nausea, vomiting; and disease-site-specific PROs, including genitourinary/sexual symptoms for patients receiving pelvic RT. RT dose alterations will be documented. Scores will be compared pre- vs post- RT. The investigators will also use standardized measures already used in EnACT, including grip strength, 30-second chair stand, timed up-and-go, and 4-stage balance. Scores will be compared pre- vs post- RT.

Registry
clinicaltrials.gov
Start Date
February 12, 2020
End Date
January 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kathleen Sturgeon

Assistant Professor

Milton S. Hershey Medical Center

Eligibility Criteria

Inclusion Criteria

  • Males and females ≥18 years of age
  • Fluent in written and spoken English
  • Must be able to provide and understand informed consent
  • Must have an ECOG PS of ≤ 2
  • Diagnosed with metastatic disease
  • Cancer patients (stage 1-4)
  • Treatment to primary site or metastatic disease
  • Scheduled to receive radiation therapy at Penn State Cancer Institute
  • Absence of absolute contraindications for exercise according to the American Heart Association (see below)
  • Primary attending oncologist approval

Exclusion Criteria

  • Receiving radiation therapy at a location other than Penn State Cancer Institute
  • Not fluent in written and spoken English
  • Evidence in the medical record of an absolute contraindication for exercise
  • Performing \> 90 minutes/week of physical activity at the time of initial evaluation
  • Cardiac exclusion criteria:
  • Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
  • History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty or stenting within the past 6 months prior to the start of radiation therapy
  • Uncontrolled arrhythmias; patients with rate controlled atrial fibrillation for \>1 month prior to start of radiation therapy may be eligible
  • acute myocarditis, pericarditis, or endocarditis
  • acute pulmonary embolus or pulmonary infarction

Outcomes

Primary Outcomes

Incidence of Treatment- Emergent Adverse Events

Time Frame: 1 year

Safety of exercise intervention: freedom from any Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher event

Acceptability of exercise intervention: (number of patients agreeing to perform RT+ET)/(number approached)

Time Frame: 1 year

(number of patients agreeing to perform RT+ET)/(number approached)

Feasibility of exercise intervention: (number of patients who completed RT+ET)/(number agreeing to perform RT+ET)

Time Frame: 1 year

(number of patients who completed RT+ET)/(number agreeing to perform RT+ET)

Secondary Outcomes

  • change in quality of life measured via the Godin Physical Activity Questionnaire(3 Months)
  • change in quality of life measured via the Barriers to Exercise RM 5-FM survey(3 Months)
  • change in quality of life measured via the Scored Patient-Generated Subjective Global Assessment(3 Months)
  • Change in timed up and go(3 Months)
  • change in quality of life measured via the Health Belief Scale(3 Months)
  • change in quality of life measured via the Work Productivity and Activity Impairment Questionnaire(3 Months)
  • change in quality of life measured via the EORTC questionnaire(3 Months)
  • change in grip strength(3 Months)
  • change in quality of life measured via the ECHO EXERT survey(3 Months)

Study Sites (1)

Loading locations...

Similar Trials